Literature DB >> 9452472

The anti-prion activity of Congo red. Putative mechanism.

S Caspi1, M Halimi, A Yanai, S B Sasson, A Taraboulos, R Gabizon.   

Abstract

PrPSc, an abnormal conformational isoform of the normal prion protein, PrPC, is the only known component of the prion, a proteinacious agent that causes fatal neurodegenerative disorders in humans and other animals. The hallmark properties of PrPSc are its insolubility in nondenaturing detergents and its resistance to digestion by proteases. Anions such as Congo red (CR) have been shown to reduce the accumulation of PrPSc in a neuroblastoma cell line permanently infected with prions as well as to delay disease onset in rodents when administrated prophylactically. The mechanism by which such anti-prion agents operate is unknown. We show here that in vitro incubation with CR renders native PrPSc resistant to denaturation by boiling SDS. This resulted from PrPSc conformation, since neither the properties of PrPC nor those of predenatured PrPSc were changed by the addition of CR. CR-PrPSc could only be denatured by the addition of acidic 3 M guanidine thiocyanate. Since in vitro conversion experiments have suggested that partial denaturation may be required for PrPSc to serve as template in the PrPC --> PrPSc conversion, we propose that CR inhibits prion propagation by overstabilizing the conformation of PrPSc molecules.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9452472     DOI: 10.1074/jbc.273.6.3484

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Immobilized prion protein undergoes spontaneous rearrangement to a conformation having features in common with the infectious form.

Authors:  E Leclerc; D Peretz; H Ball; H Sakurai; G Legname; A Serban; S B Prusiner; D R Burton; R A Williamson
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

2.  Mimicking dominant negative inhibition of prion replication through structure-based drug design.

Authors:  V Perrier; A C Wallace; K Kaneko; J Safar; S B Prusiner; F E Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

3.  Transmissible spongiform encephalopathies: in-vitro evaluation of the therapeutic potentiality of new molecules.

Authors:  G Carcassola; M L Giannino; F Riva; W Ponti
Journal:  Vet Res Commun       Date:  2003-09       Impact factor: 2.459

Review 4.  Pharmaceutical and biomedical applications of affinity chromatography: recent trends and developments.

Authors:  David S Hage; Jeanethe A Anguizola; Cong Bi; Rong Li; Ryan Matsuda; Efthimia Papastavros; Erika Pfaunmiller; John Vargas; Xiwei Zheng
Journal:  J Pharm Biomed Anal       Date:  2012-01-14       Impact factor: 3.935

5.  Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures.

Authors:  A Mangé; N Nishida; O Milhavet; H E McMahon; D Casanova; S Lehmann
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Opposite effects of dextran sulfate 500, the polyene antibiotic MS-8209, and Congo red on accumulation of the protease-resistant isoform of PrP in the spleens of mice inoculated intraperitoneally with the scrapie agent.

Authors:  V Beringue; K T Adjou; F Lamoury; T Maignien; J P Deslys; R Race; D Dormont
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 7.  Immunization treatment approaches in Alzheimer's and prion diseases.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 8.  Hormesis and medicine.

Authors:  Edward J Calabrese
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

9.  Inoculation of scrapie with the self-assembling RADA-peptide disrupts prion accumulation and extends hamster survival.

Authors:  Robert Hnasko; Cathrin E Bruederle
Journal:  PLoS One       Date:  2009-02-12       Impact factor: 3.240

10.  Oxidation of Helix-3 methionines precedes the formation of PK resistant PrP.

Authors:  Tamar Canello; Kati Frid; Ronen Gabizon; Silvia Lisa; Assaf Friedler; Jackob Moskovitz; María Gasset; Ruth Gabizon
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.